NCT05801965

Brief Summary

This is a randomized, controlled trial to assess the feasibility of Sidekick Health's digital programs for cancer patients. Participants will be treated with standard of care (SoC) in combination with the digital programs, or SoC only. We will compare the effect of the digital programs in addition to SoC to SoC only, on the cancer-related quality of life (QoL), cancer-related fatigue, and side-effect management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable cancer

Timeline
Completed

Started Apr 2023

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 24, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 6, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

April 6, 2023

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

May 25, 2025

Status Verified

March 1, 2024

Enrollment Period

1.4 years

First QC Date

March 24, 2023

Last Update Submit

May 20, 2025

Conditions

Keywords

cancerdigital solutionlifestyle changeprostate cancerquality of lifedigital interventionside effectsmedication adherencephysical activitycolorectal cancerlung cancer

Outcome Measures

Primary Outcomes (1)

  • Cancer-specific Quality of Life

    Difference in change in total score of the 30-item European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) between the intervention and control groups. The EORTC-QLQ-C30 is a 30-item questionnaire. It is composed of 28 questions with a Likert scale of 4 options where 1 represents "not at all" to 4 "very much", and 2 questions with a Likert scale of 7 options where 1 represents "very poor" to 7 "excellent". Scores on the QLQ-C30 range from 30 to 126, with a lower score representing a higher quality of life.

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

Secondary Outcomes (13)

  • Cancer-related fatigue derived from the general cancer questionnaire subscale

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

  • Cancer-related fatigue

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

  • Health-related quality of life of prostate cancer patients

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

  • Health-related quality of life of lung cancer patients

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

  • Health-related quality of life of colorectal cancer patients

    Baseline, 14 , 26, and 38 weeks after inclusion in the study

  • +8 more secondary outcomes

Study Arms (2)

Digital intervention group

EXPERIMENTAL

Participants will be instructed to download Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm. Beyond this, all participants in the interventional arm will also receive standard of care as defined for the control arm.

Device: A digital solution for patients with CancerOther: Standard of care for patients with Cancer

Standard of care - control group

ACTIVE COMPARATOR

Participants in the control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.

Other: Standard of care for patients with Cancer

Interventions

A digital program that provides holistic lifestyle intervention as well as disease education.

Also known as: SK-411 - General Oncology Program; PC-SK-451 Prostate Cancer program; CRC-SK-441; Colorectal Cancer Program LC-SK-431; Lung Cancer Program
Digital intervention group

Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.

Digital intervention groupStandard of care - control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (at least 18 years of age) diagnosed with cancer
  • Has started active cancer treatment (chemotherapy, hormonal therapy, targeted therapy, immunotherapy, radiotherapy) during the study
  • Cancer diagnosis (all stages), with a focus on prostate cancer, lung cancer, or colorectal cancer
  • Understands verbal and written Icelandic or English
  • Owning a smartphone compatible with the Sidekick Health app and capable of using it.
  • Capacity to give informed consent
  • Willing to comply with all scheduled visits, study interventions, and procedures

You may not qualify if:

  • Pregnancy
  • Surgeries in the last 4 weeks prior to participation in the study
  • Surgeries planned during the 14-weeks intervention
  • Not able to comply with study intervention or scheduled measures and visits, as assessed by oncologist
  • Current breast cancer diagnosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Landspitali University Hospital

Reykjavik, 101, Iceland

Location

Ljósið Cancer Rehabilitation Center

Reykjavik, 104, Iceland

Location

MeSH Terms

Conditions

NeoplasmsProstatic NeoplasmsColorectal NeoplasmsLung NeoplasmsMedication AdherenceMotor Activity

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Single-center prospective randomized open label pilot study
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2023

First Posted

April 6, 2023

Study Start

April 6, 2023

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

May 25, 2025

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Anonymized Individual Participant Data may be shared with other researchers for relevant research purposes following complementary ethical review and approval from the Ethical Review Board.

Locations